Investigators at Catholic University of Korea Report Findings in Factor Xa Inhibitors (Heparin-calibrated Anti-factor Xa Assay for the Measurement of Direct Anticoagulants Such As Apixaban, Rivaroxaban, and Edoxaban).

Researchers at the Catholic University of Korea conducted a study to assess the use of a heparin-calibrated anti-factor Xa assay for measuring direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban. The study aimed to determine if the antidote treatment decision level for DOACs could be established using unfractionated heparin (UFH)/low molecular weight heparin (LMWH)-calibrated AXA. The findings suggest that UFH/LMWH-calibrated AXA may be effective in determining the presence of DOACs at the cutoff level for antidote treatment in rivaroxaban and apixaban, but not in edoxaban. The research has been peer-reviewed and published in Clinical Laboratory. [Extracted from the article]